Lessee, Operating Lease, Liability, to be Paid, Year Three of Entrada Therapeutics, Inc. from 31 Mar 2022 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Entrada Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three in USD history and change rate from 31 Mar 2022 to 31 Dec 2024.
  • Entrada Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Three for the quarter ending 31 Dec 2024 was $9,083,000, a 2.9% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Three, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Three, YoY Quarterly Change (%)

Entrada Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $9,083,000 +$257,000 +2.9% 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q4 2023 $8,826,000 +$176,000 +2% 31 Dec 2023 10-K 13 Mar 2024 2023 FY
Q3 2023 $8,826,000 +$176,000 +2% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $8,826,000 +$176,000 +2% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $5,396,000 -$3,254,000 -38% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $8,650,000 31 Dec 2022 10-K 06 Mar 2023 2022 FY
Q3 2022 $8,650,000 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $8,650,000 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $8,650,000 31 Mar 2022 10-Q 12 May 2022 2022 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.